Clinical Trials

Inclusion Criteria:

• Eligible patients must have a histologically or cytologically confirmed diagnosis of adenocarcinoma of the ovary, peritoneum, or fallopian tube either by surgery, biopsy, fine-needle aspiration (FNA), paracentesis, or thoracentesis; a diagnosis of a mucinous cancer must be made by biopsy only
• International Federation of Gynecology and Obstetrics (FIGO) stage I, II, III, and IV are eligible
• Patients must have received no previous treatment for this malignancy other than surgery
• Patients must be entered within eight weeks of confirmation of disease diagnosis by surgery, biopsy, FNA, paracentesis or thoracentesis if there is no primary surgery, and within twelve weeks of primary or staging surgery if patient received primary surgery
• Absolute neutrophil count (ANC) greater than or equal to 1,500/mcl
• Platelets greater than or equal to 100,000/mcl
• Bilirubin less than or equal upper limit of normal (ULN)
• Creatinine less than or equal to 1.5 x ULN
• Patients must have a Gynecologic Oncology Group (GOG) performance status of 0, 1, 2 or 3
• Effective XX/XX/2014, only patients 75 years of age or older are eligible for enrollment; (04/23/2012) (08/12/2013)
• Patients must have recovered from the effects of recent surgery
• Patients must be free of active infection requiring antibiotics
• Patients must have signed an approved informed consent and Health Insurance Portability and Accountability Act (HIPAA)
• Patient and physician agree that they plan to conduct treatment according to Regimen 3
• Patient can read and understand sufficient English to be able to respond to questions posed by the study instruments

Exclusion Criteria:

• Patients who have received previous treatment for this malignancy other than surgery
• Patients with other invasive malignancies whose previous cancer treatment contraindicates this protocol therapy
• "Borderline tumors" (tumors of low malignant potential) by surgery or biopsy are excluded
• Patients with medical conditions that in the opinion of the investigator render treatment on this protocol unsafe should be excluded